ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Velzen, E.
Right arrow Articles by van den Bosch, J. M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Velzen, E.
Right arrow Articles by van den Bosch, J. M.M.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1999;67:903-907
© 1999 The Society of Thoracic Surgeons

Original Articles

Type of lymph node involvement and survival in pathologic N1 stage III non–small cell lung carcinoma

Edwin van Velzen, MDa, Aart Brutel de la Rivière, MD, PhDa, Hans J.J. Elbers, MD, PhDa, Jan-Willem J. Lammers, MD, PhDa, Jules M.M. van den Bosch, MD, PhDa

a Departments of Pulmonology, Thoracic Surgery, and Pathology, Sint Antonius Hospital, Nieuwegein, and Department of Pathology, University Hospital, Utrecht, the Netherlands

Accepted for publication September 24, 1998.

Address reprint requests to Dr van den Bosch, Department of Pulmonology, Sint Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands

Background. Survival of patients with stage II non–small lung cancer by the 1986 classification depends on the type of lymph node involvement (by direct extension or by metastases in lobar or hilar lymph nodes). The influence of these types of lymph node involvement on survival was investigated in pathologic N1 stage III patients.

Methods. Of 2,009 patients having operation from 1977 through 1993, the cases of 123 patients with pathologic N1 stage III disease (80 T3 N1 and 43 T4 N1) were reviewed. The N1 status was refined by the specific type of lymph node involvement.

Results. The cumulative 5-year survival rate of all hospital survivors (n = 111) was 27.2%. A significant difference in mean 5-year survival rate was observed between patients who underwent complete resection and those with incomplete resection (34.4% versus 11.4%; p = 0.0001). Further analysis was performed with hospital survivors having complete resection only (n = 76). The cumulative 5-year survival rate was 34.4%. Type of lymph node involvement did not relate to survival for the group as a whole or for the T3 and T4 subsets. Survival was not related to age, histology, type of resection, or tumor size.

Conclusions. Moderately good results can be obtained with surgical resection for stage III patients with pathologic N1 disease. In contrast with stage II, complete resection of pathologic N1 higher-stage non–small cell lung carcinoma is not influenced by type of lymph node involvement.


Related Article

John R. Benfield
Ann. Thorac. Surg. 1999 67: 907. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Marra, L. Hillejan, G. Zaboura, T. Fujimoto, D. Greschuchna, and G. Stamatis
Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis
J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 543 - 553.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.